Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.
CITATION STYLE
Amaador, K., Thieblemont, C., Trotman, J., & Minnema, M. C. (2023, November 1). Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström’s macroglobulinemia. Hematological Oncology. John Wiley and Sons Ltd. https://doi.org/10.1002/hon.3210
Mendeley helps you to discover research relevant for your work.